| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2775213 | Experimental and Molecular Pathology | 2011 | 7 Pages |
Abstract
No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC). Ligand activation of peroxisome-activated receptor (PPAR)γ induces antitumor effects in cancer but not obviously in TNBC. In TNBC cells, combined treatment with thiazolidinedione and demethylation drugs Hydralazine up-regulated protein and mRNA levels of PPARγ. Besides, the combination of two drugs promote antiproliferative and apoptotic effects in TNBC cells and decrease the proliferation index in the tumor xenografts. Taken together, our results suggest that multidrug regimens including a combination of Thiazolidinedione and Hydralazine may provide a therapeutic advantage in TNBC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Ying Jiang, Yeqing Huang, Chun Cheng, Weiqi Lu, Yixin Zhang, Xiaojuan Liu, Lin Zou, Qiwen Ben, Aiguo Shen,